Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
ADDING OLAPARIB TO ABIRATERONE PROLONGS RPFS IN MCRPC
12 března, 2021 4:43 pm Leave your thoughtsJune 4, 2018 PARP inhibition with olaparib plus antihormonal therapy with abiraterone resulted in significantly prolonged radiologic progression-free survival...
A RANDOMIZED PHASE III TRIAL BETWEEN ADJUVANT DOCETAXEL AND SURVEILLANCE AFTER RADICAL RADIOTHERAPY FOR INTERMEDIATE AND HIGH RISK PROSTATE CANCER: RESULTS OF SPCG-13 TRIAL
12 března, 2021 4:40 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Genitourinary (Prostate) Cancer Abstract number: 5000 Citation: J Clin Oncol 36,...
ADJUVANT DOCETAXEL FAILS TO IMPROVE DFS FOR INTERMEDIATE- OR HIGH-RISK PROSTATE CANCER
12 března, 2021 4:34 pm Leave your thoughtsJune 4, 2018 Treatment with docetaxel without prednisone failed to improve biochemical disease-free survival (DFS) compared with surveillance in...
GENITOURINÁRNÍ SEKCE NA ASCO 2018
12 března, 2021 4:32 pm Leave your thoughtsAdjuvantní podání docetaxelu selhalo ve snaze prodloužit DFS u nemocných s intermediálním či vysoce rizikovým prostatickým karcinomem (Adjuvant Docetaxel Fails to Improve DFS...
KEYNOTE-164: PEMBROLIZUMAB FOR PATIENTS WITH ADVANCED MICROSATELLITE INSTABILITY HIGH (MSI-H) COLORECTAL CANCER
12 března, 2021 4:30 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3514 Citation: J Clin Oncol 36,...
MFOLFOXIRI + PANITUMUMAB VERSUS FOLFOXIRI AS FIRST-LINE TREATMENT IN PATIENTS WITH RAS WILD- -TYPE METASTATIC COLORECTAL CANCER M(CRC): A RANDOMIZED PHASE II VOLFI TRIAL OF THE AIO (AIO-KRK0109)
12 března, 2021 4:27 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3509 Citation: J Clin Oncol 36,...
RANDOMIZED TRIAL OF IRINOTECAN AND CETUXIMAB (IC) VERSUS IRINOTECAN, CETUXIMAB AND RAMUCIRUMAB (ICR) AS 2ND LINE THERAPY OF ADVANCED COLORECTAL CANCER (CRC) FOLLOWING OXALIPLATIN AND BEVACIZUMB BASED THERAPY: RESULT OF E7208
12 března, 2021 4:23 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3504 Citation: J Clin Oncol 36,...
LONG-TERM RESULTS OF THE ADORE TRIAL: ADJUVANT OXALIPLATIN, LEUCOVORIN, AND 5-FLUOROURACIL (FOLFOX) VERSUS 5-FLUOROURACIL AND LEUCOVORIN (FL) AFTER PREOPERATIVE CHEMORADIOTHERAPY AND SURGERY FOR LOCALLY ADVANCED RECTAL CANCER
12 března, 2021 4:13 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3501 Citation: J Clin Oncol 36,...
HIPEC PROVIDES NO ADDITIONAL BENEFIT TO COMPLETE RESECTION IN COLORECTAL PERITONEAL CARCINOMATOSIS
12 března, 2021 4:06 pm Leave your thoughtsJune 4, 2018 The addition of oxaliplatin hyperthermic peritoneal chemotherapy (HIPEC) combined with cytoreductive surgery in patients with colorectal...
Novinky z ASCO 2018 – kolorektální karcinom
12 března, 2021 4:00 pm Leave your thoughtsNejvětšího celosvětového onkologického kongresu, pořádaného již tradičně v obřím kongresovém centru McCormick Place ve městě Chicago (Illinois, USA), se letos...